NZ researchers on cusp of new obesity treatment
Researchers at the University of Auckland are developing a new obesity treatment that targets fat storage processes rather than suppressing appetite. This approach aims to provide an alternative for patients who do not respond well to current GLP-1 medications like Wegovy.
Why it matters
As obesity rates rise globally, finding diverse pharmacological treatments that avoid muscle loss and appetite suppression could significantly improve patient outcomes.
Unlike drugs like Wegovy and Mounjaro, which suppress appetite and can result in the loss of muscle mass, this new treatment would target the body's fat-storage and leave appetite untouched.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in